{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TCS",
    "query": {
      "intervention": "TCS"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TCS&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T02:03:08.657Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03028090",
      "title": "Study to Assess Electrocardiogram Waveforms Produced Through the Utilization of the Sherlock 3CG™ Tip Confirmation System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Indication for Peripheral Intravenous Catheterization"
      ],
      "interventions": [
        {
          "name": "SHERLOCK 3CG™ Tip Confirmation System with MODUS Software",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "C. R. Bard",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2013-11",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-23",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 2,
      "location_summary": "Colorado Springs, Colorado • Montgomery, Ohio",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Montgomery",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03028090"
    },
    {
      "nct_id": "NCT03948334",
      "title": "A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "ZPL389 30mg",
          "type": "DRUG"
        },
        {
          "name": "ZPL389 50mg",
          "type": "DRUG"
        },
        {
          "name": "TCS and/or TCI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2019-04-04",
      "completion_date": "2020-08-25",
      "has_results": true,
      "last_update_posted_date": "2021-10-08",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 2,
      "location_summary": "Litchfield Park, Arizona • Fairborn, Ohio",
      "locations": [
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Fairborn",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03948334"
    },
    {
      "nct_id": "NCT03288766",
      "title": "SHERLOCK 3CG™ Diamond Tip Confirmation System",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Indication for Peripheral Intravenous Catheterization",
        "Atrial Flutter",
        "Premature Atrial Contraction",
        "Premature Ventricular Contraction",
        "Premature Junctional Contraction",
        "Tachycardia",
        "Atrioventricular Block",
        "Bundle-Branch Block"
      ],
      "interventions": [
        {
          "name": "PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "C. R. Bard",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2018-04-19",
      "completion_date": "2021-06-15",
      "has_results": false,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 6,
      "location_summary": "Las Vegas, Nevada • Greensboro, North Carolina • Greenville, North Carolina + 3 more",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03288766"
    },
    {
      "nct_id": "NCT02317276",
      "title": "A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Triamcinolone 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2014-12",
      "completion_date": "2017-04-06",
      "has_results": true,
      "last_update_posted_date": "2019-01-24",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02317276"
    },
    {
      "nct_id": "NCT06627335",
      "title": "An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pregnancy Related",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib Cream",
          "type": "DRUG"
        },
        {
          "name": "TCS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "14 Years and older · Female only"
      },
      "enrollment_count": 5621,
      "start_date": "2023-03-27",
      "completion_date": "2028-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 1,
      "location_summary": "Morrisville, North Carolina",
      "locations": [
        {
          "city": "Morrisville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06627335"
    },
    {
      "nct_id": "NCT03345914",
      "title": "Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background Treatment: Topical Corticosteroids",
          "type": "OTHER"
        },
        {
          "name": "Background Treatment: Moisturizers",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 367,
      "start_date": "2017-11-17",
      "completion_date": "2019-09-10",
      "has_results": true,
      "last_update_posted_date": "2020-08-13",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345914"
    },
    {
      "nct_id": "NCT05559359",
      "title": "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Topical Corticosteroid (TCS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 377,
      "start_date": "2022-10-18",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05559359"
    },
    {
      "nct_id": "NCT05762055",
      "title": "Prospective Comparative Analysis of ACDF vs Fusion Interbody Cages With nanoLOCK Osseointegrative Technology",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Radiculopathy",
        "Cervical Myelopathy"
      ],
      "interventions": [
        {
          "name": "Titan nanoLOCK interbody cage",
          "type": "DEVICE"
        },
        {
          "name": "ACDF interbody cage",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2024-02-05",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05762055"
    },
    {
      "nct_id": "NCT04250337",
      "title": "Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Topical Corticosteroid",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 228,
      "start_date": "2020-02-03",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 43,
      "location_summary": "Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04250337"
    },
    {
      "nct_id": "NCT00121381",
      "title": "Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Pimecrolimus plus topical corticosteroid (TCS)",
          "type": "DRUG"
        },
        {
          "name": "Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 400,
      "start_date": "2005-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2008-01-15",
      "last_synced_at": "2026-09-13T02:03:08.657Z",
      "location_count": 13,
      "location_summary": "Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121381"
    }
  ]
}